Results 91 to 100 of about 21,237 (199)

Glibenclamide treatment prevents the development of diabetes in NOD mice.

open access: yes, 2016
a) All mice had normal blood glucose levels at week 5. Thereafter, the proportion of untreated animals, which remained normoglycaemic, rapidly dropped with time (open symbols).
Helena Pontes (148291)   +5 more
core   +1 more source

Dissolution test for glibenclamide tablets

open access: yes, 2007
The aim of this work is to develop and validate a dissolution test for glibenclamide tablets. Optimal conditions to carry out the dissolution test are 500 mL of phosphate buffer at pH 8.0, paddles at 75 rpm stirring speed, time test set to 60 min and ...
Maurilio José Lara-Filho   +4 more
core   +1 more source

Intranasal Mucoadhesive In Situ Gel of Glibenclamide-Loaded Bilosomes for Enhanced Therapeutic Drug Delivery to the Brain

open access: yesPharmaceutics
Background: The neuroprotective efficacy of glibenclamide (GLIB) has been demonstrated in multiple rodent models of ischemia, hemorrhagic stroke, traumatic brain damage, spinal cord injury, and metastatic brain tumors.
Meenakshi Tripathi   +4 more
doaj   +1 more source

Glibenclamide decelerates the responses of coronary regulation in the goat

open access: yes, 1994
The role of blocking ATP-sensitive potassium (KATP) channels by glibenclamide on the dynamic responses of coronary resistance to abrupt changes in perfusion pressure and heart rate was investigated.
Dankelman, J.   +2 more
core   +2 more sources

Engineered Glibenclamide-Loaded Nanovectors Hamper Inflammasome Activation in an Ex Vivo Alzheimer’s Disease Model—A Novel Potential Therapy for Neuroinflammation: A Pilot Study

open access: yesBiomolecules
Background: Inflammasomes regulate the activation of caspases resulting in inflammation; inflammasome activation is dysregulated in Alzheimer’s disease (AD) and plays a role in the pathogenesis of this condition. Glibenclamide, an anti-inflammatory drug,
Francesca La Rosa   +17 more
doaj   +1 more source

Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer

open access: yesPharmaceuticals
The NLR family pyrin domain containing 3 (NLRP3) promotes the growth of colorectal cancer (CRC). However, the therapeutic effect of NLRP3 inhibition on CRC cell progression is controversial. This study comparatively investigated the therapeutic effect of
Shaimaa Hamza   +5 more
doaj   +1 more source

Quercetin reduce cardiomyocytes damage in type 2 diabetic rats [PDF]

open access: yesUniversa Medicina, 2014
Background Diabetes mellitus (DM) is a group of metabolic diseases which are characterized by hyperglycemia, resulting in various complications. A major macrovascular complication of DM is cardiac failure due to cardiomyopathy.
Asri Hendrawati, Nadhir
doaj  

PRENATAL DIAGNOSIS OF ROBERT/SC SYNDROME IN A DIABETIC MOTHER WITH A HISTORY OF MEBENDAZOLE AND GLIBENCLAMIDE INTAKE [PDF]

open access: yesActa Medica Iranica, 2003
The Robert/SC (pseudothalidomide) syndrome is a rare autosomal recessive disorder, associated with phocomelia and craniofacial abnormalities. An anomalous fetus with lower limb phocomelia and micromelia, lumbar myeloschisis, upper limb and ribs defects ...
M. Pourissa, S. Refahi N. Garaaghagi
doaj  

Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus

open access: yesSultan Qaboos University Medical Journal, 2012
Objectives: This study aimed to compare the effects of metformin and glibenclamide on high sensitivity serum C-reactive protein (hs-CRP) and oxidative stress, represented by serum malondialdehyde (MDA) and total antioxidant status (TAS) in newly ...
Alaa A.A. Abdulkadir, Imad A-J. Thanoon
doaj  

Vasorelaxant effects of glibenclamide on rat thoracic aorta

open access: yes, 2005
The purpose of this study was to investigate the effect of glibenclamide, a selective ATP-sensitive K+ (KATP) channel blocker, on agonist-induced contractions in isolated rat aortic rings.
Ertuna E.   +3 more
core  

Home - About - Disclaimer - Privacy